Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Clin Appl Thromb Hemost ; 27: 1076029620986877, 2021.
Article in English | MEDLINE | ID: covidwho-1158175

ABSTRACT

New York City was one of the epicenters of the COVID-19 pandemic. The management of peripheral artery disease (PAD) during this time has been a major challenge for health care systems and medical personnel. This document is based on the experiences of experts from various medical fields involved in the treatment of patients with PAD practicing in hospitals across New York City during the outbreak. The recommendations are based on certain aspects including the COVID-19 infection status as well as the clinical PAD presentation of the patient. Our case-based algorithm aims at guiding the treatment of patients with PAD during the pandemic in a safe and efficient way.


Subject(s)
COVID-19 , Pandemics , Peripheral Arterial Disease , SARS-CoV-2 , COVID-19/epidemiology , COVID-19/therapy , Humans , Peripheral Arterial Disease/epidemiology , Peripheral Arterial Disease/therapy , Peripheral Arterial Disease/virology
2.
Vasc Endovascular Surg ; 55(6): 601-611, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1117767

ABSTRACT

BACKGROUND: COVID-19 is characterized by a pulmonary interstitial compromise which can require intensive care unit (ICU) and mechanical ventilation. Covid patients develop a wide range of pathologies. This study aims to identify the impact of COVID-19 in diseases commonly treated by vascular surgeons. METHODS: Four conditions were selected: venous thromboembolism (VTE), pulmonary embolism (PE), peripheral arterial disease (PAD), and microangiopathy. A systematic review of the literature using PRISMA guidelines was. RESULTS: Out of 1195 papers reviewed for conditions in COVID-19 patients relevant to routine vascular surgery practice, 43 papers were included and analyzed. Venous thrombosis was found to be the most common COVID-19 associated pathology with a cumulative incidence of 25% at 7 days and 48% at 14 days. Additionally, D-dimer levels proved to be a good predictor, even in the early stages of the disease with a sensitivity of 85%, specificity of 88.5% and a negative predictive value of 94.7%. Patients in the ICU demonstrated a significantly higher risk of developing VTE, even when receiving pharmacologic thromboprophylaxis. Although evidence of arterial thrombosis was less common (1% to 16.3%), its consequences were typically more serious, including limb loss and death even in young individuals (OR = 25, 95% CI). Finally, microangiopathy has a wide spectrum of clinical presentations from retinal microangiopathy to other more severe manifestations such as myocardial injury, pulmonary compromise and potential multiple organ dysfunction syndrome. CONCLUSIONS: Although the pathophysiological pathway by which COVID-19 produces thrombosis is not completely clear, the incidence of both arterial and venous thrombosis is increased. D-dimer screening should be done in all COVID-19 patients, as a predictor of thrombotic complications.


Subject(s)
COVID-19/complications , Peripheral Arterial Disease/epidemiology , Pulmonary Embolism/epidemiology , Thrombotic Microangiopathies/epidemiology , Vascular Surgical Procedures/statistics & numerical data , Venous Thromboembolism/epidemiology , Humans , Peripheral Arterial Disease/surgery , Peripheral Arterial Disease/virology , Pulmonary Embolism/surgery , Pulmonary Embolism/virology , Thrombotic Microangiopathies/surgery , Thrombotic Microangiopathies/virology , Venous Thromboembolism/surgery , Venous Thromboembolism/virology
3.
Vasc Med ; 26(2): 174-179, 2021 04.
Article in English | MEDLINE | ID: covidwho-983897

ABSTRACT

The expansion of coronavirus disease 2019 (COVID-19) prompted measures of disease containment by the Italian government with a national lockdown on March 9, 2020. The purpose of this study is to evaluate the rate of hospitalization and mode of in-hospital treatment of patients with chronic limb-threatening ischemia (CLTI) before and during lockdown in the Campania region of Italy. The study population includes all patients with CLTI hospitalized in Campania over a 10-week period: 5 weeks before and 5 weeks during lockdown (n = 453). Patients were treated medically and/or underwent urgent revascularization and/or major amputation of the lower extremities. Mean age was 69.2 ± 10.6 years and 27.6% of the patients were women. During hospitalization, 21.9% of patients were treated medically, 78.1% underwent revascularization, and 17.4% required amputations. In the weeks during the lockdown, a reduced rate of hospitalization for CLTI was observed compared with the weeks before lockdown (25 vs 74/100,000 inhabitants/year; incidence rate ratio: 0.34, 95% CI 0.32-0.37). This effect persisted to the end of the study period. An increased amputation rate in the weeks during lockdown was observed (29.3% vs 13.4%; p < 0.001). This study reports a reduced rate of CLTI-related hospitalization and an increased in-hospital amputation rate during lockdown in Campania. Ensuring appropriate treatment for patients with CLTI should be prioritized, even during disease containment measures due to the COVID-19 pandemic or other similar conditions.


Subject(s)
COVID-19/epidemiology , COVID-19/virology , Extremities/physiopathology , Hospitalization/statistics & numerical data , Ischemia/epidemiology , SARS-CoV-2/pathogenicity , Adult , Aged , Aged, 80 and over , Chronic Disease , Cross-Sectional Studies , Female , Humans , Ischemia/physiopathology , Ischemia/virology , Italy/epidemiology , Male , Middle Aged , Peripheral Arterial Disease/complications , Peripheral Arterial Disease/virology , Retrospective Studies , Risk Factors
6.
J Thromb Thrombolysis ; 50(3): 543-547, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-591507

ABSTRACT

A high incidence of thrombotic events, particularly deep vein thrombosis and pulmonary embolism, has been clearly documented in COVID-19 patients. In addition, small series of patients with coronary, cerebrovascular and peripheral arterial thrombotic events have also been reported, but their true incidence and consequences are not well described, and constitute the objective of this study. From February 1st to April 21st, 2020, 2115 COVID-19 patients were treated at Hospital Universitario Fundación Alcorcón (Madrid, Spain), and 1419 were eventually admitted. Patient characteristics and outcomes were collected by reviewing their electronic medical records. Fourteen patients had a systemic arterial thrombotic event, which represents a 1% incidence in relation to the total number of hospitalized patients. Three patients suffered an acute coronary syndrome, two with persistent ST-segment elevation, one of whom was treated invasively, and one with transient ST-segment elevation. Eight patients had a cerebrovascular event. Six suffered an acute ischemic stroke and two a transient ischemic attack, 50% of them had a Rankin score ≥ 3 at discharge. Three additional patients had a limb thrombotic event, all of them infrapopliteal, and were managed conservatively. All three cases developed necrosis of the toes, two of them with bilateral involvement. The hospitalization death rate of patients with an arterial event was 28.6%. Although COVID-19 may favor the occurrence of thrombotic events, the destabilization and thrombosis of arterial atherosclerotic plaques do not seem to be a frequent mechanism which warrants the need for specific systematic preventive measures.


Subject(s)
Acute Coronary Syndrome/epidemiology , Coronavirus Infections/epidemiology , Peripheral Arterial Disease/epidemiology , Pneumonia, Viral/epidemiology , Stroke/epidemiology , Thrombosis/epidemiology , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/virology , Aged , Aged, 80 and over , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/virology , Female , Host-Pathogen Interactions , Humans , Incidence , Male , Middle Aged , Pandemics , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/virology , Pneumonia, Viral/diagnosis , Pneumonia, Viral/virology , Prognosis , Retrospective Studies , Risk Assessment , Risk Factors , SARS-CoV-2 , Spain/epidemiology , Stroke/diagnosis , Stroke/virology , Thrombosis/diagnosis , Thrombosis/virology
SELECTION OF CITATIONS
SEARCH DETAIL